Other SMARCA4-deficient Malignant Tumors (With PI Approval)
1 clinical trials · Condition
◉ Watch Other SMARCA4-deficient Malignant Tumors (With PI Approval)
| Record | Firm | Date |
|---|---|---|
| Study of Nivolumab and Ipilimumab in Children and Young Adults With INI1-Negative Cancers (NCT04416568) | Dana-Farber Cancer Institute | 2020-08-14 |
Track Other SMARCA4-deficient Malignant Tumors (With PI Approval) automatically
Every clearance here is in the API, with alerts when new ones post.